Axim Biotechnologies(OTC) AXIM

Market Cap$1.16M

Since IPO (2013)-94%

5 Year-99%

1 Year-31%

1 Month+2%

$0.00

+3.03%

+0.00Today

Axim Biotechnologies last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-08-21

Axim Biotechnologies stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-26.09%	USD 0.00	2026-08-14
1 month	+1.64%	USD 0.00	2026-07-22
3 month	-40.87%	USD 0.01	2026-05-22
Year to date	-68.22%	USD 0.01	2025-12-31
1 year	-30.61%	USD 0.00	2025-08-21
3 year	-83%	USD 0.02	2023-08-22
5 year	-99.48%	USD 0.65	2021-08-20
Since inception	-94.33%	USD 0.06	2013-10-09

Axim Biotechnologies Financials at a Glance

Market Cap

$1.16M

Revenue (TTM)

$391.99K

Net Income (TTM)

-$818.45K

EPS (TTM)

-$0.00

P/E Ratio

-1.42

Dividend

$0.00

Beta (Volatility)

0.26 (Low)

Dividend

$0.00

Beta (Volatility)

0.26 (Low)

Price

$0.00

Volume

235,831

Open

$0.00

Price

$0.00

Volume

235,831

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.03

Estimated Earnings Date

Apr 13, 2026

Dividend

$0.00

Beta (Volatility)

0.26 (Low)

Price

$0.00

Volume

235,831

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.03

Estimated Earnings Date

Apr 13, 2026

AXIM News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Axim Biotechnologies

AXIM Biotechnologies, Inc. specializes in advanced diagnostic solutions for healthcare, focusing on critical areas such as COVID-19, ocular health, and cancer treatment. The company is developing rapid diagnostic assays and serological tests to enhance patient care and disease management.

Products and Services

Rapid diagnostic assays for SARS-CoV-2 neutralizing antibodies
Serological tests to assess immune response to COVID-19
Innovative tear tests for dry eye disease and oncology treatments

Growth Outlook

Expansion into COVID-19 diagnostics aligns with ongoing global health needs
Innovative ocular health solutions target a growing market for eye care
Oncology pipeline includes promising anti-metastatic therapies

Financial Highlights

Q2 2026 revenue of $206,990, showing growth from Q1 2026
Gross profit margin improved to 47.1% in Q2 2026
Operating expenses decreased significantly, indicating cost management efforts

AXIM Biotechnologies, Inc. is positioned in the biotechnology sector, focusing on innovative diagnostic solutions that address pressing healthcare challenges. The company's commitment to developing rapid tests for COVID-19 and other health conditions reflects its adaptability in a dynamic market. Recent financial data indicates a positive trend in revenue and gross profit margins, suggesting effective operational strategies. The ongoing development of its oncology pipeline further enhances its potential for growth, making it an intriguing option for investors interested in the biotechnology field.

AI Generated • Aug 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

John W. Huemoeller, II

Website

www.aximbiotech.com

Headquarters

San Diego, CA 92121, US

AXIM Financials

Key Financial Metrics (TTM)

Gross Margin

-8.71%

Operating Margin

-268.08%

Net Income Margin

-208.79%

Return on Equity

7.37%

Return on Capital

N/A

Return on Assets

-24.88%

Earnings Yield

-70.42%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.16M

Shares Outstanding

340.46M

Volume

235.83K

Avg. Volume

367.48K

Financials (TTM)

Gross Profit

-$34.15K

Operating Income

-$1.05M

EBITDA

-$633.45K

Operating Cash Flow

$706.61K

Capital Expenditure

$5.00

Free Cash Flow

$706.61K

Cash & ST Invst.

$10.40K

Total Debt

$7.78M

Axim Biotechnologies Performance Analysis

Axim Biotechnologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 8,875	-85.3%
2023	2023-12-31	USD 39,518	345.3%
2024	2024-12-31	USD 70,458	78.3%
2025	2025-12-31	USD 0	N/A

Axim Biotechnologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	11.9%

Axim Biotechnologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.04	-69.1%
2023	2023-12-31	USD -0.04	-6.1%
2024	2024-12-31	USD -0.01	-68.9%
2025	2025-12-31	USD -0.00	-71.8%

Axim Biotechnologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-375.0%
Q4	2025-12-31	-54.5%
Q1	2026-03-31	152.9%
Q2	2026-06-30	-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$206.99K

N/A

Gross Profit

$97.51K

+190.2%

Gross Margin

47.11%

N/A

Market Cap

$1.16M

N/A

Market Cap/Employee

$165.37K

N/A

Employees

N/A

Net Income

-$188.15K

-238.4%

EBITDA

-$1.24K

-100.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$10.40K

+271.2%

Total Debt

$7.78M

+3.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$7.78M

+4.6%

Short Term Debt

$0.00

-100.0%

Return on Assets

-24.88%

N/A

Return on Invested Capital

36.82%

N/A

Free Cash Flow

-$8.97K

+98.7%

Operating Cash Flow

-$8.98K

+98.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ARUXFAcrux Limited

ARUXFAcrux Limited$0.00+0.00%

LVVVLiveWire Ergogenics, Inc.

LVVVLiveWire Ergogenics, Inc.$0.00+0.00%

PKTXProtoKinetix, Incorporated

PKTXProtoKinetix, Incorporated$0.00+0.00%

SIGYSigyn Therapeutics, Inc.

SIGYSigyn Therapeutics, Inc.$0.03+0.00%

REPCFRepliCel Life Sciences Inc.

REPCFRepliCel Life Sciences Inc.$0.00+0.00%

RDDTFRadient Technologies Inc.

RDDTFRadient Technologies Inc.$0.00+0.00%

HAVLFHAVN Life Sciences Inc.

HAVLFHAVN Life Sciences Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.77+0.10%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$43.68+0.06%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.41+0.06%

MARAMara Holdings

MARAMara Holdings$11.26+0.01%

NVDANvidia

NVDANvidia$214.72-0.01%

INTCIntel

INTCIntel$90.07-0.02%

MRNAModerna

MRNAModerna$145.13+0.09%

Questions About AXIM

What is the current price of Axim Biotechnologies?

Axim Biotechnologies is trading at $0.00 per share.

What is the 52-week range for Axim Biotechnologies?

Over the past 52 weeks, Axim Biotechnologies has traded between $0.00 and $0.03.

How much debt does Axim Biotechnologies have?

As of the most recent reporting period, Axim Biotechnologies reported total debt of $7.78M.

How much cash does Axim Biotechnologies have on hand?

Axim Biotechnologies reported $10.40K in cash and cash equivalents in its most recent financial results.

What is Axim Biotechnologies’s dividend yield?

Axim Biotechnologies does not currently have a dividend yield.

Axim Biotechnologies(OTC) AXIM

Axim Biotechnologies Financials at a Glance

AXIM News

3 Marijuana Stocks You Couldn't Pay Me to Buy

3 Marijuana Stocks That Like to Live Life Dangerously

2 Marijuana Stocks That Have Imploded Since August Began

2 Marijuana Stocks That Turned $10,000 Into $125,000 and $300,000, Respectively

This Marijuana Stock Is Up 2,500%, but It Has 2 Major Red Flags

The Average Marijuana Stock Is Up 332% Over the Past Year

3 Things You Need to Know About Marijuana Stock Axim Biotechnologies

4 Marijuana Stocks Looking to Combat the Opioid Epidemic

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Axim Biotechnologies

AXIM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Axim Biotechnologies Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AXIM

What is the current price of Axim Biotechnologies?

What is the 52-week range for Axim Biotechnologies?

How much debt does Axim Biotechnologies have?

How much cash does Axim Biotechnologies have on hand?

What is Axim Biotechnologies’s dividend yield?

Premium Investing Services